Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Massachusetts General Hospital
EMD Serono
Alliance for Clinical Trials in Oncology
St. Jude Children's Research Hospital
Eli Lilly and Company
Seattle Children's Hospital
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Children's Oncology Group
Seattle Children's Hospital
AbbVie
Institut Curie
Eastern Cooperative Oncology Group
Baylor College of Medicine
Rigshospitalet, Denmark
In8bio Inc.
National Cancer Institute (NCI)
Institut Curie
European Organisation for Research and Treatment of Cancer - EORTC